Veteran investor Vijay Kedia has made a strategic investment in Mahamaya Lifesciences Ltd, an SME-listed pharmaceutical company, by acquiring close to 9 lakh equity shares through a recent block deal. The transaction is estimated to be worth around ₹12.5 crore, according to market data.

Mahamaya Lifesciences operates in the pharmaceutical and healthcare segment, focusing on the marketing and distribution of generic medicines across multiple therapeutic areas. Its product portfolio includes antibiotics, anti-malarial, anti-diabetic, and other essential drugs, catering primarily to regulated and semi-regulated international markets.

The company follows an asset-light operating model, outsourcing manufacturing while concentrating on product selection, branding, regulatory approvals, and market penetration. This approach allows Mahamaya Lifesciences to maintain flexibility, control costs, and protect operating margins, even as it expands its product offerings and geographic footprint.

Over the past few years, Mahamaya Lifesciences has steadily scaled its business by expanding its portfolio and strengthening its presence across export markets, positioning itself as a niche player within the SME pharma space. The company’s strategy aligns with broader investor preferences for capital-efficient models and predictable revenue streams.

Vijay Kedia’s entry is being viewed by the market as a strong endorsement of the company’s fundamentals, business scalability, and long-term growth visibility. The move comes at a time when investors are increasingly selective in the SME segment, favouring companies with clearer earnings potential and sustainable business models over speculative listing-driven valuations.